Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Endocrinology | Family Medicine

Cushing's Disease Clinical Trials

A listing of Cushing's Disease medical research trials actively recruiting patient volunteers. Use the filters below to narrow your search results.

Filter by:

Phase:

Gender:

Age:

Location:

 

First 1 2 3 Last 

Arizona

Peoria Arizona 85381

Patients are needed to participate in a clinical research study of Pasireotide sub-cutaneous formulation to evaluate Cushing's Disease

Phoenix Arizona 85013

Patients are needed to participate in a clinical research study of Pasireotide sub-cutaneous formulation to evaluate Cushing's Disease

California

Los Angeles California 90095

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Los Angeles California 90095

Patients are needed to participate in a clinical research study of Pasireotide sub-cutaneous formulation to evaluate Cushing's Disease

San Diego California 92108

Patients are needed to participate in a clinical research study of Pasireotide sub-cutaneous formulation to evaluate Cushing's Disease

Stanford California 94304

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Torrance California 90509

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

View More ▼

Torrance California 90502

Patients are needed to participate in a clinical research study of Pasireotide sub-cutaneous formulation to evaluate Cushing's Disease

Georgia

Atlanta Georgia 30322

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Illinois

Chicago Illinois 60612

Patients are needed to participate in a clinical research study of Pasireotide sub-cutaneous formulation to evaluate Cushing's Disease

Maryland

UPDATED

Johns Hopkins University School of Medicine Division of Endocrinology, Diabetes & Metabolism
Baltimore Maryland 21287

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

View More ▼

Baltimore Maryland 21287

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Baltimore Maryland 21201

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Massachusetts

UPDATED

Massachusetts General Hospital
Boston Massachusetts 02114

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Michigan

UPDATED

University of Michigan Medical Center Rares de la Surrénale, Service d'Endocrinologie, Hôpital Cochin
Ann Arbor Michigan 48109

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

View More ▼

Ann Arbor Michigan 48109-0944

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Nebraska

Omaha Nebraska 68131

Patients are needed to participate in a clinical research study of Pasireotide sub-cutaneous formulation to evaluate Cushing's Disease

New Mexico

UPDATED

University of New Mexico HSC Center Rares de la Surrénale, Service d'Endocrinologie, Hôpital Cochin
Albuquerque New Mexico 87131

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

New York

UPDATED

Icahn School of Medicine at Mount Sinai
New York New York 10029

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

View More ▼

New York New York 10029

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Ohio

UPDATED

Cleveland Clinic Endocrinology
Cleveland Ohio 44195

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

UPDATED

CarePoint East
Columbus Ohio 43203

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Oregon

UPDATED

Oregon Health & Science University
Portland Oregon

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

View More ▼

Portland Oregon 97201

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Portland Oregon 97239

Patients are needed to participate in a clinical research study of Pasireotide sub-cutaneous formulation to evaluate Cushing's Disease

Pennsylvania

UPDATED

University of Pennslyvania Smilow Center for Translational Research
Philadelphia Pennsylvania 19104-5160

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

View More ▼

Philadelphia Pennsylvania 19104

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Philadelphia Pennsylvania 19104

Patients are needed to participate in a clinical research study of Pasireotide sub-cutaneous formulation to evaluate Cushing's Disease

Pittsburgh Pennsylvania 15212

Patients are needed to participate in a clinical research study of Pasireotide sub-cutaneous formulation to evaluate Cushing's Disease

Tennessee

Nashville Tennessee 37212-3139

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Nashville Tennessee 37203

Patients are needed to participate in a clinical research study of Pasireotide sub-cutaneous formulation to evaluate Cushing's Disease

Wisconsin

Milwaukee Wisconsin 53226

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Belgium

UPDATED

UZLeuven Dienst endocrinologie
Leuven International

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

France

UPDATED

Endocrinologie, Pavillon des Ecrins Centre Hospitalier Universitaire, Hopital Nord
Cedex International

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

UPDATED

Hôpital de la TIMONE Department of Endocrinology and Reference Center for Rare Pituitary Diseases
Marseille International

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

UPDATED

Centre de Réference Maladies Rares de la Surrénale, Service d'Endocrinologie, Hôpital Cochin
Paris International 75014

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Israel

UPDATED

Institute of Endocrinology & Metabolism Rabin Medical Center, Beilinson Campus
Petah Tiqva International 49100

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Netherlands

UPDATED

Erasmus MC, Dpt. Of Internal Medicine, Division of Endocrinology Centre Hospitalier Universitaire, Hopital Nord
Rotterdam International

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Spain

UPDATED

Hospital Universitario de la Ribera Centre Hospitalier Universitaire, Hopital Nord
Alzira-Valencia International

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

UPDATED

Hospital Sant Pau, Universitat Autònoma de Barcelona
Barcelona International 08025

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Argentina

Buenos Aires C1232AAC

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Cordoba X5009BSN

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Belgium

Brussel 1090

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Bruxelles 1200

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Bruxelles 1070

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Edegem 2650

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Gent 9000

A Phase 2 clinical study for patients with Cushing's Disease

View More ▼

Gent 9000

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

Leuven 3000

A Phase 2 clinical study for patients with Cushing's Disease

Leuven 3000

Patients are needed to participate in a clinical research study evaluating SOM230 LAR 30 mg and SOM230 LAR 10 mg for the treatment of Cushing's Disease

First 1 2 3 Last 

Receive E-mails About New Clinical Trials!

Sign up for our FREE service and we'll send you automatic email notifications as soon as a clinical trial is posted in the medical category you're interested in.